Physician profile
Akshal Patel
NPI 1598226524
$973.04
in general payments reported to CMS, 2019-2025
17 companies · $973 in 2025
The $973 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $190.55 | 2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $105.64 | 2025 | Glassia |
| Astrazeneca Pharmaceuticals LP | $102.40 | 2025 | Fasenra, Tezspire |
| Viatris Specialty LLC | $96.67 | 2025 | Yupelri |
| Insmed, INC. | $73.61 | 2025 | Brinsupri, Arikayce |
| Electromed, INC. | $61.85 | 2025 | Smartvest |
| Avadel Cns Pharmaceuticals, LLC | $54.96 | 2025 | Lumryz |
| Harmony Biosciences LLC | $46.48 | 2025 | |
| Mallinckrodt Hospital Products INC. | $45.09 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $33.23 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.57 | 2025 | |
| Grifols USA, LLC | $28.54 | 2025 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $23.57 | 2025 | Nuzyra |
| Genzyme Corporation | $22.01 | 2025 | |
| Inspire Medical Systems, INC. | $20.78 | 2025 | Inspire |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $19.77 | 2025 | Zemaira |
| Verona Pharma, INC. | $18.32 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akshal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.